TARRYTOWN, N.Y., Sept. 20 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS) today announced that it will participate
in the 2nd Annual Oppenheimer Diabetes Conference, being held at the
Madison Towers, Jolly Hotel in New York City. Michael M. Goldberg, M.D.,
Chairman and Chief Executive Officer, will present on Thursday, September
21, 2006, at 1:40 p.m. Eastern Time.
The presentation will be broadcast live via the Internet. You may
access the presentation by visiting the investor relations portion within
the Emisphere Technologies' website, http://www.emisphere.com/ir.asp or directly
at: http://www.internetvideochannel.com/oppenheimer/diabetes.asp
Please visit either site at least five minutes prior to start time for
instructions. Corresponding slides will also be posted to the Investor
Relations portion of Emisphere's website. A replay of the presentation will
be available through October 27, 2006.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company pioneering
the oral delivery of otherwise injectable drugs. Emisphere's business
strategy is to develop oral forms of injectable drugs, either alone or with
corporate partners, by applying its proprietary eligen(R) technology to
those drugs or licensing its eligen(R) technology to partners who typically
apply it directly to their marketed drugs. Emisphere's eligen(R) technology
has enabled the oral delivery of proteins, peptides, macromolecules and
charged organics. Emisphere and its partners have advanced oral
formulations or prototypes of salmon calcitonin, heparin, insulin,
parathyroid hormone, human growth hormone and cromolyn sodium into clinical
trials. Emisphere has strategic alliances with world-leading pharmaceutical
companies. For further information, please visit http://www.emisphere.com .
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by
representatives of Emisphere relating to matters that are not historical
facts (including without limitation those regarding the timing or potential
outcomes of research collaborations or clinical trials, any market that
might develop for any of Emisphere's product candidates and the sufficiency
of Emisphere's cash and other capital resources) are forward-looking
statements that involve risks and uncertainties, including, but not limited
to, the likelihood that future research will prove successful, the
likelihood that any product in the research pipeline will receive
regulatory approval in the United States or abroad, the ability of
Emisphere and/or its partners to develop, manufacture and commercialize
products using Emisphere's drug delivery technology, Emisphere's ability to
fund such efforts with or without partners, and other risks and
uncertainties detailed in Emisphere's filings with the Securities and
Exchange Commission, including those factors discussed under the caption
"Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615)
filed on March 16, 2006.
SOURCE Emisphere Technologies, Inc.
 back to top
Related links:
http://www.emisphere.com
http://www.emisphere.com/ir.asp
http://www.internetvideochannel.com/oppenheimer/diabetes.asp
CONTACT:
Stewart Siskind, Investor Relations of
Emisphere Technologies, Inc., +1-914-785-4742; or Media, Dan
Budwick of BMC Communications for Emisphere Technologies, Inc.,
+1-212-477-9007 ext. 14
|
